Skip to main content

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

Written by Customer Service on . Posted in Public Companies.

  
  
 Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

 

4. October 2024
Company Announcement no. 24

  

With reference to company announcement no. 19, on 3 June 2024, the extraordinary general meeting in Pharma Equity Group A/S approved a reduction of the company’s share capital by a nominal value of DKK 920,667,494.70 from a nominal value of DKK 1,022,963,883.00 to a nominal value of DKK 102,296,388.30 by allocation to a specific reserve pursuant to section 188(1)(3) of the Danish Companies Act.

 

The capital reduction has today been finally registered with the Danish Business Authority and has been carried out by way of a proportional reduction of the denomination of all the company’s shares, meaning that the denomination of the shares is reduced from DKK 1.00 to DKK 0.1.
  
Nasdaq Copenhagen has been informed about the capital reduction which will be effected in Nasdaq Copenhagen’s systems soonest possible. Pharma Equity Group A/S’ updated articles of associations can be found at the company’s website.
 
In accordance with section 32 of the Danish Capital Markets Act, Pharma Equity Group A/S hereby announces that its share capital then amounts to a nominal value of DKK 102,296,388.30, corresponding to 1,022,963,883 shares of nominally DKK 0.1 each and a total of 1,022,963,883 voting rights.

 

 

For further information, please contact:

 

 Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114

Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222

  

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group’s primary objective is to bring significant value to Reponex Pharmaceuticals’ medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals’ medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.